ArticleCureus2025
Tezepelumab After Mepolizumab in Allergic Bronchopulmonary Mycosis: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Tezepelumab in severe asthma with pulmonary mucus plugs and eosinophilic chronic rhinosinusitis after dupilumab intolerance and suboptimal mepolizumab response: A case report.Respiratory medicine case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We describe the case of a 43-year-old woman with allergic bronchopulmonary mycosis (ABPM) and severe asthma who improved clinically on mepolizumab with eosinophil suppression but had recurrent mucus plugs, persistent right-middle-lobe atelectasis, rising fractional exhaled nitric oxide (FeNO), and high total IgE levels. Following a switch to tezepelumab, she attained sustained symptom control, no systemic steroid-requiring exacerbations, substantial FeNO and IgE decline, and radiologic reduction of mucus plugs and atelectasis. This case illustrates that residual upstream type 2 activity can persist despite IL-5 blockade, and thymic stromal lymphopoietin (TSLP) inhibition may address this gap by concurrently attenuating multiple effectors. In mucus-predominant allergic bronchopulmonary aspergillosis/ABPM with high FeNO/IgE levels after anti-IL-5 therapy, phenotype- and biomarker-guided sequencing of anti-TSLP antibodies may be considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.